AntiViral Research Center In the Department of Medicine

Welcome to the AVRC

Innovation in HIV Research

The UC San Diego AntiViral Research Center (AVRC) develops and conducts innovative research that enhances the quality and duration of life for people living with HIV infection and other infections of global significance. The award-winning research center is an established leader in San Diego’s HIV research community and is well known for its HIV testing programs. Internationally, the AVRC extends its research and education programs to Africa, Asia, and South America.

Upcoming Events
HIV Long-Term Survivors Awareness Day Jun 05, 2016 12:00 AM
AVRC Community Advisory Board Jun 06, 2016 05:30 PM - 07:00 PM — AVRC, First Floor Conference Room, 220 Dickinson Street, Suite A, San Diego, CA 92103
HIV-Positive Aging Forum presented by POZabilities Jun 11, 2016 09:30 AM - 04:15 PM — Majorca Room of the Casa del Prado, Balboa Park
Upcoming events…


Successful diagnosis of acute/early HIV infections may have contributed to fall in HIV incidence in San Diego
An HIV testing programme [The Early Test] targeting individuals with acute/early infection likely contributed to a decline in incident infections in San Diego after 2008, investigators report in Clinical Infectious Diseases.
An HIV Prevention Pill for Transgender Persons
UC launches first in the nation demonstration project
UC San Diego AVRC Hosts National HIV Scientists for 2015 Cure Conference
A collaborative HIV Cure Conference features presentations by researchers at the forefront of new cure advancements on June 16
‘Testing for Tickets’ Encourages HIV Testing, Offers Free LGBT Pride Festival Tickets
Innovative HIV testing campaign offers 250 free LGBT Pride Festival tickets to people who get tested starting June 15 and continuing until supplies run out
HIV Transmission Networks Mapped to Reduce Infection Rate
Susan Little, MD maps San Diego's HIV transmission network, identifies transmission "hot spots"
Treatment for HIV Should Start within Four Months of Infection
Study by AVRC researchers identifies optimum window for initiating antiretrovial therapy for CD-4+ T-cell recovery

External Resources: